Xiamen has twice revised the policies for the biomedicine industry since the enactment to continuously intensify the support. Since 2016, Xiamen Science and Technology Bureau (XSTB) has redeemed the total incentive fund of more than 0.486 billion yuan promised by biomedicine policies. Under the ever-growing support, the industry sees unceasing development and remarkable industrial highlights. In 2021, the biomedicine and health industry of Xiamen had an output of 91.583 billion yuan, up by 167.8% over that of 2015 which was 34.198 billion yuan, making it one of China's main export bases of COVID-19 detection reagents. Due to the increasing innovation capability of enterprises in recent years, a torrent of well-known biomedical enterprises have kept emerging, such as Wantai Biopharm, AmoyDx, Amoytop Biotech, and Double Medical, making the biomedicine and health industry the most technologically innovative and progressive strategic emerging industry in Xiamen. The city also boasts the world's first hepatitis E vaccine, the first nerve growth factor officially approved for clinical purposes, China's first cervical cancer vaccine, and other innovative products.
